Sysmex Corporation
SSMXY
Other OTC8.98
USD
-0.11
- -
CIK
0001517231
ISIN
US87184P1093
CUSIP
87184P109
Return %
Stock
S&P500
1Y
-45.31
26.53
3Y
-62.05
76.60
5Y
-71.81
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Hisashi Ietsugu
- Full Time Employees
- 10,042
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1-5-1, Wakinohama-Kaigandori Kobe Japan 651-0073
- IPO Date
- Oct 17, 2011
- CIK
- 0001517231
- Website
- sysmex.co.jp
- Similar Companies
- Business
- Sysmex Corporation develops, manufactures and markets diagnostic instruments, reagents and related software for in vitro diagnostics, with a global leadership position in hematology analyzers and expertise in hemostasis, urinalysis, immunochemistry, clinical chemistry and laboratory automation; the company also provides solutions in oncology, clinical flow cytometry, cytogenetic testing and informatics software to support healthcare workflows in laboratories worldwide. Founded in 1968 and headquartered in Kobe, Japan, Sysmex operates in more than 190 countries and regions through an extensive network of subsidiaries, sales offices and manufacturing facilities, including recent expansions in India, Brazil, Greece and Kenya, serving national hospitals, private clinics, universities and research institutions. Core product lines encompass automated hematology analyzers such as the XR-Series and XN-Series; hemostasis systems like the CN-Series; urinalysis instruments including the UF-Series; immunoassay platforms under the HISCL brand for parameters in hypertension, diabetes, Alzheimer's risk assessment and infectious diseases; clinical chemistry analyzers; and integrated automation solutions for laboratory efficiency. In recent developments, Sysmex agreed in September 2025 to acquire JEOL Ltd.'s clinical chemistry testing business, including the BioMajesty analyzer line, with completion targeted for April 2026 to bolster its portfolio and accelerate global expansion under its VA33 long-term strategy. The company established new subsidiaries in Greece in June 2025 and Kenya in April 2025 to strengthen direct sales and customer support in Europe and East Africa, while completing its largest manufacturing base in India in 2025 for local production of reagents and instruments, and expanding production facilities in Brazil and Nagano, Japan. Additional strategic moves include a partnership with QIAGEN in October 2025 for exclusive distribution of clinical diagnostic products in infectious diseases and oncology in Japan, an expanded alliance with CellaVision for advanced hematology morphology analyzers, and a collaboration with Nissay in June 2025 for digital healthcare solutions; Sysmex plans to relocate its global headquarters within Kobe City in spring 2028 coinciding with its 60th anniversary.
Alphatec (NASDAQ:ATEC) and Sysmex (OTCMKTS:SSMXY) Critical Survey
Thermo Fisher Scientific (NYSE:TMO) versus Sysmex (OTCMKTS:SSMXY) Head to Head Contrast
Sysmex (OTCMKTS:SSMXY) vs. DexCom (NASDAQ:DXCM) Head to Head Survey
Sysmex Corporation ADR (OTCMKTS:SSMXY) Short Interest Down 42.7% in February
Short Interest in Sysmex Corporation ADR (OTCMKTS:SSMXY) Decreases By 53.9%
Short Interest in Sysmex Corporation ADR (OTCMKTS:SSMXY) Increases By 601.3%
Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors